Price | 3500€+ |
Organism | Human |
Product Type | iPS-derived organoid |
Tissue | Gastric |
Disease | – |
Applications
-
Our newly developed drug differs from previously known therapeutics in that it directly penetrates various tumor tissues to exert its efficacy. Therefore, it was essential to analyze the drug’s penetration...
We have been developing products utilizing various bacterial strains and have explored multiple methods to evaluate the efficacy of our developed strains. However, due to the nature of obligate anaerobic...
Organoids overcome the limitations of traditional 2D cell culture models by enabling more physiologically relevant experiments in a 3D, multicellular environment. In particular, utilizing both tumor and normal organoids allows...
Organoid has proven to be a powerful tool for human sample-based validation in the drug development process. In this study, CRC organoids were utilized to evaluate the efficacy of candidate...
The tumor organoid efficacy evaluation platform has proven to be an invaluable tool for assessing the anticancer potential of small molecules. Using CRC organoids to validate human POC based on...
In Thailand, cholangiocarcinoma is a prevalent disease. While many companies have traditionally relied on 2D cell models and mouse models for drug development, these approaches often face challenges in clinical...
The virus platform has proven its innovative potential in developing infection models using organoids. It significantly accelerated the development of antiviral drugs and enabled precise drug evaluation in a human-like...
As an expert with 20 years of experience in novel drug development, I firmly believe that tumor organoids are an innovative technology enabling accurate evaluation by comparing patient-derived cancer and...
Colorectal cancer, unlike other cancer types, is significantly influenced by dietary and lifestyle factors. Evaluating drug responsiveness based on specific genetic markers and MSI (microsatellite instability) in patients is crucial,...
Our NK immune cell-based cancer therapy faced challenges during its development and efficacy evaluation. To address these issues, we explored various platforms and discovered the Lambda Biologics platform, which we...
COSMAX는 글로벌 화장품 업계를 선도하며, 혁신적인 원료 개발과 제품 효능 평가에 ODISEI SKIN 플랫폼을 도입하여 놀라운 결과를 경험했습니다. 이를 통해 발모, 탈모, 새치 등 신규 화장품 원료의 잠재력을 신뢰성 있게...
Human intestinal organoids can accurately mimic the structure and function of the human intestine, making them an ideal platform for studying the early stages of organ development. The KRIBB research...
LambdaBiologics is supporting toxicity evaluation and efficacy verification for pet pharmaceutical products and functional foods through its innovative organoid platform, offering an alternative to animal testing. Platform Potential Proven Through...
LambdaBiologics provides OECD-guideline-based testing services verified under GLP standards through its innovative research platform and diverse preclinical solutions. The company ensures optimal cost efficiency and performance for its clients, supporting...
Leveraging advancements in stem cell technology, we are pioneers in developing human gastric organoids derived from both tissue samples and induced pluripotent stem cells (iPSCs). Our state-of-the-art techniques facilitate precise gastric differentiation from iPSCs, enabling the creation of highly functional and physiologically relevant gastric organoids. These organoids are invaluable tools for experimental research and therapeutic innovation.
Our gastric organoids closely mimic the key structural features of human stomach tissue, replicating the morphology of the gastric epithelium, including critical structures like gastric glands. They are composed of various cell types, including parietal cells, chief cells, mucous cells, and enteroendocrine cells, accurately reflecting the functional complexity of real gastric tissue.
Lambda Biologics GmbH
Deutscher Platz 5 c, 04103, Leipzig, Germany
info@lambdabiologics.com
